Defective phagocytosis in airways disease

Chest

Volumn 141, Issue 4, 2012, Pages 1055-1062

  Donnelly, Louise E ^a   Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; AZITHROMYCIN; PATTERN RECOGNITION RECEPTOR; SULFORAPHANE;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; APOPTOSIS; ASTHMA; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CELL SURFACE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DISEASE ACTIVITY; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG CLEARANCE; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT FAILURE;

EID: 84859508650     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2348     Document Type: Article

References (81)

1. Hiemstra PS. Defensins and cathelicidins in inflammatory lung disease: beyond antimicrobial activity. Biochem Soc Trans. 2006;34(pt 2):276-278.
2. Holmskov U, Thiel S, Jensenius JC. Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol. 2003;21:547-578. (Pubitemid 37174541)
3. Sallenave JM. Antimicrobial activity of antiproteinases. Biochem Soc Trans. 2002;30(2):111-115.
4. Martin TR, Frevert CW. Innate immunity in the lungs. Proc Am Thorac Soc. 2005;2(5):403-411. (Pubitemid 43128033)
5. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev. 2000;173(1):39-51. (Pubitemid 30095209)
6. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity . Nat Rev Immunol. 2005;5(12):953-964. (Pubitemid 41746764)
7. Berenson CS, Garlipp MA, Grove LJ, Maloney J, Sethi S. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis. 2006;194(10):1375-1384. (Pubitemid 44706505)
8. McClure CD, Schiller NL. Inhibition of macrophage phagocytosis by Pseudomonas aeruginosa rhamnolipids in vitro and in vivo. Curr Microbiol. 1996;33(2):109-117. (Pubitemid 26286240)
9. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol. 2002;20(1):825-852. (Pubitemid 34293441)
10. Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest. 2006;129(6):1673-1682. (Pubitemid 43895000)
11. Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol. 2003;81(4):289-296. (Pubitemid 36904336)
12. Bianchi SM, Prince LR, McPhillips K, et al. Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2008;177(1):35-43.
13. Greenberg S, Grinstein S. Phagocytosis and innate immunity. Curr Opin Immunol. 2002;14(1):136-145. (Pubitemid 34085118)
14. Allen LA, Aderem A. Molecular definition of distinct cytoskeletal structures involved in complement- and Fc receptormediated phagocytosis in macrophages. J Exp Med. 1996; 184(2):627-637. (Pubitemid 26324116)
15. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999;17:593-623. (Pubitemid 29241135)
16. García-García E, Rosales C. Signal transduction during Fc receptor-mediated phagocytosis. J Leukoc Biol. 2002;72(6): 1092-1108. (Pubitemid 36008879)
17. Swanson JA, Hoppe AD. The coordination of signaling during Fc receptor-mediated phagocytosis. J Leukoc Biol. 2004;76(6):1093-1103. (Pubitemid 39602944)
18. Arredouani M, Yang Z, Ning Y, et al. The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. J Exp Med. 2004;200(2): 267-272. (Pubitemid 38982186)
19. Arredouani MS, Palecanda A, Koziel H, et al. MARCO is the major binding receptor for unopsonized particles and bacteria on human alveolar macrophages. J Immunol. 2005;175(9):6058-6064. (Pubitemid 41508092)
20. Stuart LM, Ezekowitz RA. Phagocytosis: elegant complexity. Immunity. 2005;22(5):539-550. (Pubitemid 40719190)
21. Palecanda A, Kobzik L. Receptors for unopsonized particles: the role of alveolar macrophage scavenger receptors. Curr Mol Med. 2001;1(5):589-595. (Pubitemid 33772037)
22. Tricker E, Cheng G. With a little help from my friends: modulation of phagocytosis through TLR activation. Cell Res. 2008;18(7):711-712. (Pubitemid 351948233)
23. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250-258.
24. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15(2):194-222. (Pubitemid 34303763)
25. Singh AM, Busse WW. Asthma exacerbations. 2: aetology. Thorax. 2006;61(9):809-816.
26. Vergne I, Chua J, Lee HH, Lucas M, Belisle J, Deretic V. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2005; 102(11):4033-4038. (Pubitemid 40388550)
27. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS ONE. 2011;6(2):e16384.
28. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD. 2004;1(1):59-70.
29. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest. 2002;121(suppl 5):151S-155S. (Pubitemid 34497333)
30. Ritts RE, Miller RD, LeDuc PV, Offord KP. Phagocytosis and cutaneous delayed hypersensitivity in patients with chronic obstructive pulmonary disease. Chest. 1976;69(4):474-478.
31. Fietta A, Bersani C, De Rose V, et al. Evaluation of systemic host defense mechanisms in chronic bronchitis. Respiration. 1988;53(1):37-43.
32. Nielsen H, Bonde J. Association of defective monocyte chemotaxis with recurrent acute exacerbations in chronic obstructive lung disease. Eur J Respir Dis. 1986;68(3):200-206. (Pubitemid 16126334)
33. Tortorella C, Ottolenghi A, Moretti AM, Jirillo E, Antonaci S. Thymostimulin administration modulates polymorph metabolic pathway in patients with chronic obstructive pulmonary disease. Immunopharmacol Immunotoxicol. 1992;14(3):421-437.
34. Fietta A, Merlini C, De Bernardi PM, Gandola L, Piccioni PD, Grassi C. Non specific immunity in aged healthy subjects and in patients with chronic bronchitis. Aging (Milano). 1993;5(5):357-361. (Pubitemid 24140466)
35. Linden M, Larson M, Prellner T, Brattsand R, Laitinen LA. Seasonal variation in the function of blood monocytes obtained from healthy nonsmokers, asymptomatic smokers, and smokers with chronic bronchitis. Chronobiol Int. 1994;11(4):266-272. (Pubitemid 2112425)
36. Vecchiarelli A, Dottorini M, Puliti M, Todisco T, Cenci E, Bistoni F. Defective candidacidal activity of alveolar macrophages and peripheral blood monocytes from patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991;143(5 pt 1):1049-1054.
37. Müns G, Rubinstein I, Bergmann KC. Phagocytosis and oxidative burst of blood phagocytes in chronic obstructive airway disease. Scand J Infect Dis. 1995;27(4):369-373.
38. Ferrara F, D'Adda D, Falchi M, Dall'Asta L. The macrophagic activity of patients affected by pneumonia or chronic obstructive pulmonary disease. Int J Tissue React. 1996;18(4-6):109-114. (Pubitemid 27245143)
39. Prieto A, Reyes E, Bernstein ED, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferón). Am J Respir Crit Care Med. 2001;163(7):1578-1583. (Pubitemid 32578759)
40. Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J. 2010;35(5):1039-1047.
41. Lundborg M, Dahlén SE, Johard U, et al. Aggregates of ultra fine particles impair phagocytosis of microorganisms by human alveolar macrophages. Environ Res. 2006;100(2):197-204. (Pubitemid 43155272)
42. Lundborg M, Johard U, Låstbom L, Gerde P, Camner P. Human alveolar macrophage phagocytic function is impaired by aggregates of ultrafine carbon particles. Environ Res. 2001;86(3):244-253.
43. Martí-Lliteras P, Regueiro V, Morey P, et al. Nontypeable Haemophilus influenzae clearance by alveolar macrophages is impaired by exposure to cigarette smoke. Infect Immun. 2009;77(10):4232-4242.
44. Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2007;37(6): 748-755. (Pubitemid 350211645)
45. Löfdahl JM, Wahlström J, Sköld CM. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers. Clin Exp Immunol. 2006;145(3):428-437. (Pubitemid 44252484)
46. Pons AR, Noguera A, Blanquer D, Sauleda J, Pons J, Agustí AG. Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD. Eur Respir J. 2005; 25(4):647-652. (Pubitemid 40528757)
47. Kirkham P. Oxidative stress and macrophage function: a failure to resolve the inflammatory response. Biochem Soc Trans. 2007;35(pt 2):284-287. (Pubitemid 46596491)
48. Kirkham PA, Spooner G, Rahman I, Rossi AG. Macrophage phagocytosis of apoptotic neutrophils is compromised by matrix proteins modified by cigarette smoke and lipid peroxidation products. Biochem Biophys Res Commun. 2004;318(1):32-37. (Pubitemid 38526241)
49. Richens TR, Linderman DJ, Horstmann SA, et al. Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA. Am J Respir Crit Care Med. 2009:179.
50. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178(2):139-148. (Pubitemid 351957772)
51. Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res. 2005;6:68-76.
52. Pons J, Sauleda J, Regueiro V, et al. Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease. Respir Res. 2006; 7(1):64-73.
53. Harvey CJ, Thimmulappa RK, Sethi S, et al. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci Transl Med. 2011;3(78):78ra32.
54. Stringer KA, Tobias M, O'Neill HC, Franklin CC. Cigarette smoke extract-induced suppression of caspase-3-like activity impairs human neutrophil phagocytosis. Am J Physiol Lung Cell Mol Physiol. 2007;292(6):L1572-L1579. (Pubitemid 47077373)
55. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007;62(4):360-367.
56. Haase G, Skopnik H, Groten T, Kusenbach G, Posselt HG. Long-term fungal cultures from sputum of patients with cystic fibrosis. Mycoses. 1991;34(9-10):373-376.
57. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138(5):699-704. (Pubitemid 32417671)
58. Thomassen MJ, Boxerbaum B, Demko CA, Kuchenbrod PJ, Dearborn DG, Wood RE. Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages. Pediatr Res. 1979;13(9):1085-1088. (Pubitemid 9218594)
59. Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol. 2006;8(9):933-944. (Pubitemid 44314724)
60. Wright AKA, Rao S, Range S, et al. Pivotal Advance: Expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors. J Leukoc Biol. 2009;86(3): 479-489.
61. Vandivier RW, Fadok VA, Ogden CA, et al. Impaired clearance of apoptotic cells from cystic fibrosis airways. Chest. 2002;121(suppl 3):89S. (Pubitemid 34248373)
62. Vandivier RW, Fadok VA, Hoffmann PR, et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest. 2002;109(5):661-670. (Pubitemid 34204845)
63. Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest. 2007;132(6):1962-1966.
64. Alexis NE, Soukup J, Nierkens S, Becker S. Association between airway hyperreactivity and bronchial macrophage dysfunction in individuals with mild asthma. Am J Physiol Lung Cell Mol Physiol. 2001;280(2):L369-L375.
65. Lay JC, Alexis NE, Zeman KL, Peden DB, Bennett WD. In vivo uptake of inhaled particles by airway phagocytes is enhanced in patients with mild asthma compared with normal volunteers. Thorax. 2009;64(4):313-320.
66. Fitzpatrick AM, Holguin F, Teague WG, Brown LA. Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma. J Allergy Clin Immunol. 2008;121(6):1372-1378.
67. Fitzpatrick AM, Teague WG, Burwell L, Brown MS, Brown LA; NIH/NHLBI Severe Asthma Research Program. Glutathione oxidation is associated with airway macrophage functional impairment in children with severe asthma. Pediatr Res. 2011;69(2):154-159.
68. Alexis NE, Eldridge MW, Peden DB. Effect of inhaled endotoxin on airway and circulating inflammatory cell phagocytosis and CD11b expression in atopic asthmatic subjects. J Allergy Clin Immunol. 2003;112(2):353-361. (Pubitemid 36981376)
69. Oliver BGG, Lim S, Wark P, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax. 2008;63(6):519-525. (Pubitemid 351831162)
70. Krysko O, Holtappels G, Zhang N, et al. Alternatively activated macrophages and impaired phagocytosis of S.-áaureus in chronic rhinosinusitis. Allergy. 2011;66(3):396-403.
71. Mascellino MT, Delogu G, Pelaia MR, Ponzo R, Parrinello R, Giardina A. Reduced bactericidal activity against Staphylococcus aureus and Pseudomonas aeruginosa of blood neutrophils from patients with early adult respiratory distress syndrome. J Med Microbiol. 2001;50(1):49-54. (Pubitemid 32042806)
72. Hirsh M, Mahamid E, Bashenko Y, Hirsh I, Krausz MM. Overexpression of the high-affinity Fcgamma receptor (CD64) is associated with leukocyte dysfunction in sepsis. Shock. 2001;16(2):102-108. (Pubitemid 33596742)
73. Berger M, Sorensen RU, Tosi MF, Dearborn DG, Döring G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest. 1989;84(4):1302-1313. (Pubitemid 19247604)
74. Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch . J Clin Invest. 1990;86(1):300-308. (Pubitemid 20227005)
75. Alexis NE, Muhlebach MS, Peden DB, Noah TL. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. J Cyst Fibros. 2006;5(1):17-25. (Pubitemid 43137157)
76. Morris MR, Doull IJM, Dewitt S, Hallett MB. Reduced iC3b-mediated phagocytotic capacity of pulmonary neutrophils in cystic fibrosis. Clin Exp Immunol. 2005;142(1):68-75. (Pubitemid 41361007)
77. Tirouvanziam R, Gernez Y, Conrad CK, et al. Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc Natl Acad Sci U S A. 2008;105(11):4335-4339. (Pubitemid 351754381)
78. Vecchiarelli A, Dottorini M, Pietrella D, et al. Macrophage activation by N-acetyl-cysteine in COPD patients. Chest. 1994;105(3):806-811. (Pubitemid 24088460)
79. Hodge S, Matthews G, Mukaro V, et al. Cigarette smoke-induced changes to alveolar macrophage phenotype and function is improved by treatment with procysteine. Am J Respir Cell Mol Biol. 2011;44(5):673-681.
80. Brown LA, Ping XD, Harris FL, Gauthier TW. Glutathione availability modulates alveolar macrophage function in the chronic ethanol-fed rat. Am J Physiol Lung Cell Mol Physiol. 2007;292(4):L824-L832. (Pubitemid 46608230)
81. Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol. 2006;176(12):7657-7665. (Pubitemid 43849066)